Bone Biologics Corporation
PosiFunda Ratios Only on PositoAI
PositoAI's own ratios from Bone Biologics Corporation's yearly results (2022–2025), compared with Healthcare companies in United States. Tap ? on any ratio for what it means.
What stands out
- Shareholder Slice Ratio: Share count rose 16,795% in 3 years, so each share's slice of the company became smaller. Bigger rise in share count than 96% of Healthcare companies in United States.
Cash quality
Profit Cash Ratio
—Data incomplete
Self-Funding Ratio
—Data incomplete
Cash Locked Ratio
—Data incomplete
Growth quality
Steadiness Ratio
0/3 · 2/3Sales grew in 0 of the last 3 years; profit grew in 2 of 3.
Less steady than 70% of Healthcare companies in United States.
Growth Efficiency Ratio
—Data incomplete
Asset Productivity Ratio
—Data incomplete
Balance-sheet strength
Debt Due Cover Ratio
—Data incomplete
Cash Cushion Ratio
—Data incomplete
Tangible Assets Ratio
—Data incomplete
Tangible Net Worth Ratio
—Data incomplete
Shareholders
Standard fundamentals
P/E, P/B, ROE, debt, growth and more (9)
Bone Biologics Corporation made a loss over the last year. Bone Biologics Corporation owes $0.12 for every $1 it owns. Bone Biologics Corporation made a loss in each of the last two years.
Compared with Healthcare companies in United States · latest annual results Dec 2025.
P/E ratio
LossBone Biologics Corporation made a loss over the last year, so its P/E ratio is not meaningful.
P/B ratio
0.28The share price is 0.28 times Bone Biologics Corporation's book value per share, lower than 96% of Healthcare companies in United States.
Market cap
$1 MThe total market value of all of Bone Biologics Corporation's shares at today's price (share price × number of shares), smaller than almost all Healthcare companies in United States. PosiCap size class: Nano Cap.
Net worth (book value)
$4 MWhat Bone Biologics Corporation would have left on paper if it sold everything it owns and paid everything it owes, from its latest balance sheet (30 Jun 2026).
Book value per share
$1.42Net worth divided by the number of shares. The share price of $0.41 is 0.3 times this, which is the P/B above.
Return on equity (ROE)
-55.0%Bone Biologics Corporation lost 55.0% of its shareholders' money over the last year, lower than 54% of Healthcare companies in United States.
Owes vs Owns
0.12×Bone Biologics Corporation owes $0.12 for every $1 it owns (low), lower than 85% of Healthcare companies in United States.
Dividend yield
NoneBone Biologics Corporation does not currently pay a dividend.
Profit growth
LossBone Biologics Corporation made a loss in each of the last two years.
Questions
How is P/B calculated on PositoAI?
P/B is market cap divided by net worth from the latest balance sheet. For Bone Biologics Corporation: $1 M ÷ $4 M (30 Jun 2026) = 0.3.
What is Bone Biologics Corporation's return on equity?
Bone Biologics Corporation lost 55.0% of its shareholders' money over the last year, lower than 54% of Healthcare companies in United States.
How much does Bone Biologics Corporation owe compared with what it owns?
Bone Biologics Corporation owes $0.12 for every $1 it owns (low), lower than 85% of Healthcare companies in United States.
Does Bone Biologics Corporation pay a dividend?
No. Bone Biologics Corporation does not currently pay a dividend.
Figures from the company's yearly results and PositoAI's own data. Full tables are on the Go Deep tab. What each figure means. PositoAI is for research and education only and is not investment advice.